Related Experiment Video
Updated: May 27, 2025
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Intranasal dupilumab improves responsiveness to steroid in an asthma mouse model
Baraa Khalid Salah Al-Sheakly1, Fatemeh Saheb Sharif-Askari1,2, Narjes Saheb Sharif-Askari1,3
1Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Aims:
The study aimed to evaluate the efficacy of local intranasal delivery of dupilumab, a monoclonal antibody targeting IL-4Rα, in comparison to intraperitoneal delivery in a mouse model of steroid-hyporesponsive asthma, a condition characterized by limited therapeutic options.
Methods:
Dupilumab was administered via both intranasal and intraperitoneal routes to a mouse model of steroid-hyporesponsive asthma. The efficacy of the treatment was assessed through histological evaluations of inflammation and goblet cell metaplasia, analysis of immune cell infiltration in bronchoalveolar lavage fluid via cytospin, and measurement of total airway resistance using FlexiVent. Additionally, gene and protein expression related to steroid hypo-responsiveness and tissue remodeling were analyzed.
Results:
Intranasal administration of dupilumab significantly reduced inflammation and goblet cell metaplasia in the bronchial epithelium. It also led to a decrease in immune cell infiltration in bronchoalveolar lavage fluid and reduced total airway resistance. Furthermore, the intranasal dupilumab-treated group exhibited lower expression of genes and proteins associated with steroid hypo-responsiveness and tissue remodeling.
Conclusions:
Our findings demonstrate that intranasal administration of dupilumab not only effectively reduces inflammation but also significantly reverses steroid hypo-responsiveness and tissue remodeling, outperforming systemic delivery. Thus, local intranasal administration of dupilumab offers superior therapeutic benefits in managing steroid-hyporesponsive asthma.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:23Inhaled Medications